The use of riamilovir as part of combination antiviral therapy in adult population

In recent years, there has been a significant increase in the incidence of various viral infections among the adult population. These infections pose a serious threat to human health, as they can lead to the development of severe complications and even death. Antiviral therapy is a key element in the fight against these diseases, but existing drugs are often not effective enough. Therefore, the development of new, more effective and safe drugs is an urgent task of modern medicine. In this regard, the search for new approaches to the treatment of viral infections is becoming relevant, one of which may be the use of riamilovir as part of complex antiviral therapy. Riamilovir is an antiviral etiotropic drug that was developed specifically to combat RNA viral infections. It has a broad spectrum of action and is able to suppress the replication of viruses, thereby preventing their spread in the body. Riamilovir acts by blocking the enzymes necessary for the reproduction of the virus. This mechanism helps prevent further spread of the infection and speed up the patient’s recovery. The drug is well tolerated, and side effects are minimal, which makes it safe for use in patients with various concomitant pathologies. However, it is important to consider contraindications, such as individual intolerance to the components of the drug. The article provides a brief review of scientific literature devoted to the study of the effectiveness of antiviral complex therapy using the drug Riamilovir, and also presents a clinical observation of a patient with rapid relief of acute respiratory infection against the background of timely treatment.

1. Loosen SH, Plendl W, Konrad M, Tanislav C, Luedde T, Roderburg C, Kostev K. Prevalence of Upper Respiratory Tract Infections Before, During, and After the COVID-19 Pandemic in Germany: A Cross-Sectional Study of 2 167 453 Outpatients. J Prim Care Community Health. 2023;14:21501319231204436. https://doi.org/10.1177/21501319231204436.

2. Sandybayev N, Beloussov V, Strochkov V, Solomadin M, Granica J, Yegorov S. Characterization of viral pathogens associated with symptomatic upper respiratory tract infection in adults during a low COVID-19 transmission period. PeerJ. 2023;11:e15008. https://doi.org/10.7717/peerj.15008.

3. Lynch JP 3rd, Kajon AE. Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment. Semin Respir Crit Care Med. 2021;42(6):800–821. https://doi.org/10.1055/s-0041-1733802.

4. Azh N, Barzkar F, Motamed-Gorji N, Pourvali-Talatappeh P, Moradi Y, Vesal Azad R et al. Nonsteroidal anti-inflammatory drugs in acute viral respiratory tract infections: An updated systematic review. Pharmacol Res Perspect. 2022;10(2):e00925. https://doi.org/10.1002/prp2.925.

5. Brendish NJ, Clark TW. Antiviral treatment of severe non-influenza respiratory virus infection. Curr Opin Infect Dis. 2017;30(6):573–578. https://doi.org/10.1097/QCO.0000000000000410.

6. Lowe MC. Childhood Respiratory Conditions: Lower Respiratory Tract Infection. FP Essent. 2022;513:20–24. Available at: https://pubmed.ncbi.nlm.nih.gov/35143151/.

7. Davis B, Rothrock AN, Swetland S, Andris H, Davis P, Rothrock SG. Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis. J Am Coll Emerg Physicians Open. 2020;1(4):533–548. https://doi.org/10.1002/emp2.12128.

8. Manchal N, Mohamed MRS, Ting M, Luetchford H, Francis F, Carrucan J, Norton R. Hospital acquired viral respiratory tract infections: An under-recognized nosocomial infection. Infect Dis Health. 2020;25(3):175–180. https://doi.org/10.1016/j.idh.2020.02.002.

9. Kozlov KV, Maltsev OV, Kasyanenko KV, Sukachev VS, Lyashenko YuI, Kosuhina AA. Comparative assessment of the clinical effectiveness of direct-acting antiviral drugs in outpatient patients with acute respiratory viral infections. Terapevticheskii Arkhiv. 2024;96(8):797–803. (In Russ.) https://doi.org/10.26442/00403660.2024.08.202911.

10. Brendish NJ, Clark TW. Antiviral treatment of severe non-influenza respiratory virus infection. Curr Opin Infect Dis. 2017;30(6):573–578. https://doi.org/10.1097/QCO.0000000000000410.

11. Wong SS, Yuen KY. Antiviral therapy for respiratory tract infections. Respirology. 2008;13(7):950–971. https://doi.org/10.1111/j.1440-1843.2008.01404.x.

12. Yamaya M, Kikuchi A, Sugawara M, Nishimura H. Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases. Respir Investing. 2023;61(2):270–283. https://doi.org/10.1016/j.resinv.2022.11.002.

13. Malík I, Kováč G, Hudecova L. The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences. Ceska Slov Farm. 2022;71(6):239–244. https://doi.org/10.5817/CSF2022-6-239.

14. Artem’ev GA, Rusinov VL, Kopchuk DS, Savchuk MI, Santra S, Ulomsky EN et al. Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir (“Triazavirin®”) active against SARS-CoV-2 (COVID-19). Org Biomol Chem. 2022;20(9):1828–1837. https://doi.org/10.1039/d1ob02125g.

15. Sabitov AU, Sorokin PV, Dashutina SY. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19). Terapevticheskii Arkhiv. 2021;93(4):435–439. (In Russ.) https://doi.org/10.26442/00403660.2021.04.200751.

16. Maltsev OV, Kasyanenko KV, Kozlov KV, Zhdanov KV, Lapikov II. Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection. Terapevticheskii Arkhiv. 2022;94(10):1171–1176. (In Russ.) https://doi.org/10.26442/00403660.2022.10.201920.

17. Kasyanenko KV, Kozlov KV, Maltsev OV, Lapikov II, Gordienko VV, Sharabhanov VV et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv. 2021;93(3):290–294. (In Russ.) https://doi.org/10.26442/00403660.2021.03.200719.

18. Zhdanov KV, Maltsev OV, Kasyanenko KV, Kozlov KV, Sukachev VS, Lvov NI et al. Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults. Terapevticheskii Arkhiv. 2023;95(11):930–936. (In Russ.) https://doi.org/10.26442/00403660.2023.11.202471.

19. Sabitov AU, Lioznov DA, Zhdanov KV, Tikhonova EP, Esaulenko EV, Kovtun OP et al. Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19. Terapevticheskii Arkhiv. 2024;96(5):517–522. (In Russ.) https://doi.org/10.26442/00403660.2024.05.202770.

20. Chupakhin ON, Rusinov VL, Varaksin MV, Ulomskiy EN, Savateev KV, Butorin II et al. Triazavirin – A Novel Effective Antiviral Drug. Int J Mol Sci. 2022;23(23):14537. Available at: https://www.mdpi.com/1422-0067/23/23/48.

21. Spasov AA, Kucheryavenko AF, Sirotenko VS, Gaidukova KA, Uskov GM. Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide Intoxication. Bull Exp Biol Med. 2022;173(1):41–45. https://doi.org/10.1007/s10517-022-05489-0.